Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | TransCon IL-2 beta/gamma + TransCon TLR7/8 Agonist |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
TransCon IL-2 beta/gamma | TransCon IL-2b/g | TransCon IL-2 beta/gamma is a hydrogel based formulation of an IL-2 variant, which may lead to activation of cytotoxic T-lymphocytes and NK cells, and increased antitumor immune response, potentially resulting in tumor cell death (NCI Drug Dictionary). | ||
TransCon TLR7/8 Agonist | Resiquimod Hydrogel-based Sustained-release formulation | TLR7 Agonist 12 TLR8 Agonist 9 | TransCon TLR7/8 Agonist is a hydrogel based formulation of an imidazoquinolinamine and resiquimod, which acts as an agonist of TLR 7 and TLR8, which potentially activates the antitumor immune response and may lead to tumor cell lysis (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05980598 | Phase II | Pembrolizumab + TransCon TLR7/8 Agonist TransCon IL-2 beta/gamma + TransCon TLR7/8 Agonist Pembrolizumab | TransCon (TC) TLR7/8 Agonist, TC IL-2 beta/gamma, Pembrolizumab Prior to Surgery for Advanced Head and Neck Squamous Cell Carcinoma (BelieveIT-201) | Recruiting | USA | POL | ITA | HUN | ESP | DEU | 2 |